Jie Bao

This study uses ReSisTrace to identify pre-sensitizing agents for FLT3 inhibitors in FLT3-ITD-positive AML by analyzing transcriptional signatures and validating compounds that enhance treatment efficacy.

This study identifies BX-912 as a therapeutic agent for ovarian serous carcinoma, revealing HES1 as a target and showing synergistic effects with olaparib.

This study identifies molecular mechanisms of carfilzomib resistance in multiple myeloma using multi-omics data from cell lines and patient samples, revealing potential drug combinations to overcome resistance.

This study introduces a gene essentiality signature to predict drug mechanisms of action and target interactions, showing improved accuracy over existing methods.

This study uses multipartite network models to predict effective drug combinations and patient subclasses in acute myeloid leukemia using drug response data.